, Volume 26, Issue 4, pp 140–145 | Cite as

Voetproblematiek bij een oncologisch behandeltraject

De rol van de podotherapeut bij de oncologische voet
  • Petra Renders
  • Donja Lansink


Het aantal mensen met kanker neemt toe en dit betekent dat ook binnen de podotherapeutische praktijk deze patiëntencategorie vaker wordt gezien. De incidentie van bijwerkingen als een hand-voetsyndroom of een hand-voet-huidreactie hangt bij deze patiënten nauw samen met de middelen die gebruikt worden en de dosering van deze middelen binnen het oncologische behandeltraject. Maar wat moet je hier als podotherapeut over weten?


oncologie hand-voetsyndroom hand-voet-huidreactie 


  1. 1.
    IKNL. Dataset incidentie alle tumoren 2017. Beschikbaar via Geraadpleegd op 22 september 2018.Google Scholar
  2. 2.
    Nagore E, Insa A, Sanmartin O. Antineoplastic therapy-induced palmar plantar erythrodysesthesia (‘hand-foot’) syndrome. Incidence, recognition and management. Am J Clin Dermatol. 2000;1(4):225–34.CrossRefPubMedGoogle Scholar
  3. 3.
    Chen M, Chen J, Peng X, Xu Z, Shao J, Zhu Y, et al. The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome. Environ Toxicol Pharmacol. 2017;49:81–8.CrossRefPubMedGoogle Scholar
  4. 4.
    Miller KK, Gorcey L, McLellan BN. Chemotherapy-induced hand-foot syndrome and nail changes: a review of clinical presentation, etiology, pathogenesis, and management. J Am Acad Dermatol. 2014;71(4):787–94.CrossRefPubMedGoogle Scholar
  5. 5.
    Zuehlke RL. Erythematous eruption of the palms and soles associated with mitotane therapy. Dermatologica. 1974;148(2):90–2.CrossRefPubMedGoogle Scholar
  6. 6.
    Hueso L, Sanmartín O, Nagore E, Botella-Estrada R, Requena C, Llombart B, et al. Chemotherapy-induced acral erythema: a clinical and histopathologic study of 44 cases. Actas Dermosifiliogr. 2008;99(4):281–90.CrossRefPubMedGoogle Scholar
  7. 7.
    Babacan T, Efe O, Hasirci AS, Demirci F, Buyukhatipoglu H, Balakan O, et al. Efficacy of capecitabine monotherapy as the first-line treatment of metastatic HER2-negative breast cancer. Tumori. 2015;101(4):418–23.CrossRefPubMedGoogle Scholar
  8. 8.
    Hofheinz RD, Heinemann V, Weikersthal LF von, Laubender RP, Gencer D, Burkholder I, et al. Capecitabine-associated hand-foot-skin reaction is an independent clinical predictor of improved survival in patients with colorectal cancer. Br J Cancer. 2012;107(10):1678–83.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Stintzing S, Fischer von Weikersthal L, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, et al. Correlation of capecitabine-induced skin toxicity with treatment efficacy in patients with metastatic colorectal cancer: results from the German AIO KRK-0104 trial. Br J Cancer. 2011;105(2):206–11.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, et al. Capecitabine versus 5‑fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X‑ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. Ann Oncol. 2012;23(5):1190–7.CrossRefPubMedGoogle Scholar
  11. 11.
    Ayash LJ, Elias A, Ibrahim J, Schwartz G, Wheeler C, Reich E, et al. High-dose multimodality therapy with autologous stem-cell support for stage IIIB breast carcinoma. J Clin Oncol. 1998;16(3):1000–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Samuels BL, Vogelzang NJ, Ruane M, Simon MA. Continuous venous infusion of doxorubicin in advanced sarcoma. Cancer Treat Rep. 1987;71:971–2.PubMedGoogle Scholar
  13. 13.
    O’Brien ME, Wigler N, Inbar M, Rosso R, Grischke E, Santoro A, et al. Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol. 2004;15(3):440–9.CrossRefPubMedGoogle Scholar
  14. 14.
    Sehouli J, Oskay-Ozcelik G, Kuhne J, Stengel D, Hindenburg HJ, Klare P, et al. Biweekly pegylated liposomal doxorubicin in patients with relapsed ovarian cancer: results of a multicenter phase-II trial. Ann Oncol. 2006;17(6):957–61.CrossRefPubMedGoogle Scholar
  15. 15.
    Strauss HG, Hemsen A, Karbe I, Lautenschlager C, Persing M, Thomssen C. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer. Anticancer Drugs. 2008;19(5):541–5.CrossRefPubMedGoogle Scholar
  16. 16.
    Degen A, Alter M, Schenck F, Satzger I, Volker B, Kapp A, et al. The hand-foot-syndrome associated with medical tumor therapy – classification and management. J Dtsch Dermatol Ges. 2010;8(9):652–61.PubMedGoogle Scholar
  17. 17.
    Zimmerman GC, Keeling JH, Burris HA, Cook G, Irvin R, Kuhn J, et al. Acute cutaneous reactions to docetaxel, a new chemotherapeutic agent. Arch Dermatol. 1995;131(2):202–6.CrossRefPubMedGoogle Scholar
  18. 18.
    Gabra H, Cameron DA, Lee LE, Mackay J, Leonard RC. Weekly doxorubicin and continuous infusional 5‑fluorouracil for advanced breast cancer. Br J Cancer. 1996;74(12):2008–12.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Azad NS, Aragon-Ching JB, Dahut WL, Gutierrez M, Figg WD, Jain L, et al. Hand-foot skin reaction increases with cumulative sorafenib dose and with combination anti-VEGF therapy. Clin Cancer Res. 2009;15(4):1411–6.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Chu D, Lacouture M, Fillos T, Wu S. Risk of hand-foot skin reaction with Sorafenib: a systematic review and meta-analysis. Acta Oncol. 2008;47:176–86.CrossRefPubMedGoogle Scholar
  21. 21.
    Lee WJ, Lee JL, Chang SE, Lee MW, Kang YK, Choi JH, et al. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib. Br J Dermatol. 2009;161(5):1045–51.CrossRefPubMedGoogle Scholar
  22. 22.
    Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on Sorafenib and Sunitinib. Oncology. 2009;77(5):257–71.CrossRefPubMedGoogle Scholar
  23. 23.
    Rosenbaum SE, Wu S, Newman MA, West DP, Kuzel T, Lacouture ME. Dermatological reactions to the multitargeted tyrosine kinase inhibitor sunitinib. Support Care Cancer. 2008;16(6):557–66.CrossRefPubMedGoogle Scholar
  24. 24.
    Fischer A, Wu S, Ho AL, Lacouture ME. The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2013;31(3):787–97.CrossRefPubMedGoogle Scholar
  25. 25.
    Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME. The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Invest New Drugs. 2012;30(4):1773–81.CrossRefPubMedGoogle Scholar
  26. 26.
    Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–12.CrossRefPubMedGoogle Scholar
  27. 27.
    Boussemart L, Routier E, Mateus C, Opletalova K, Sebille G, Kamsu-Kom N, et al. Prospective study of cutaneous side-effects associated with the BRAF inhibitor vemurafenib: a study of 42 patients. Ann Oncol. 2013;24(6):1691–7.CrossRefPubMedGoogle Scholar
  28. 28.
    Chu D, Lacouture ME, Weiner E, Wu S. Risk of hand-foot skin reaction with the multitargeted kinase inhibitor Sunitinib in patients with renal cell and non-renal cell carcinoma: a meta-analysis. Clin Genitourin Cancer. 2009;7(1):11–9.CrossRefPubMedGoogle Scholar
  29. 29.
    Son H‑S, Lee WY, Lee W‑S, Yun SH, Chun H‑K. Compliance and effective management of the hand-foot syndrome in colon cancer patients receiving Capecitabine as adjuvant chemotherapy. Yonsei Med J. 2009;50(6):796–802.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    NCI. Common terminology criteria for adverse events version 5.0. November 27, 2018. Bethesda, Rockville: Nationale Institutes of Health, National Cancer Institute; 2017. Scholar

Copyright information

© Bohn Stafleu van Loghum is een imprint van Springer Media B.V., onderdeel van Springer Nature 2018

Authors and Affiliations

  1. 1.Podotherapie AstenAstenNederland
  2. 2.PodiaxOldenzaalNederland

Personalised recommendations